Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of the efficacy of Evusheld on the protection of patients with metastatic cancer from COVID-19.

The Department is currently assessing Evusheld, which includes requesting clinicians to advise on the most appropriate option for the National Health Service with the available data, the public health situation and other treatments available. We expect to receive clinical advice shortly.

The Therapeutics Clinical Review Panel provides advice on the most appropriate patient cohorts for new COVID-19 therapies, including preventative treatments. However, we are currently unable to confirm the efficacy of Evusheld for specific patient groups. Final clinical policies and eligibility would be proposed by the NHS and agreed by the United Kingdom Chief Medical Officers.